AUPH: Rega marang dodolan Aurinia Pharmaceuticals Inc

Logo korporat perusahaan Aurinia Pharmaceuticals Inc (AUPH)

Aurinia Pharmaceuticals (AUPH) maintains a pricing power advantage due to its first-mover status in lupus nephritis therapy with Lupkynis. The company's P/S ratio clearly demonstrates the market valuation of this asset, where 6.60 indicates the current level. The strategy is based on implementing an oral standard of care in immunology. Financial stability relies on strong liquidity, despite dependence on the pace of new patient acquisition.

Kapitalisasi marang pendapatan: Aurinia Pharmaceuticals (AUPH) kanggo 04.07.2022 - 16.11.2026

Rincian analitis perusahaan auriniapharma.com (AUPH)

- informasi kapitalisasi pasar:
Analisis fundamental perusahaan:Aurinia Pharmaceuticals Inc. (AUPH)
Produk dadi Aurinia Pharmaceuticals

Aurinia Pharmaceuticals (AUPH) ensures the supply of high-cost drugs for the therapy of autoimmune pathologies through a diversified network of international pharmacy hubs. By analyzing the P/S time series, an investor compares market capitalization with actual revenue, which allows for a real-time assessment of the business value relative to sales volume and determines whether the current price is undervalued or reflects hidden operational risks.

Perusahaan pesaing

argenx - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BNTX (biontech.de)|Abivax Corp (ABVX) - Rega marang dodolan|ADMA Corp - Multiplikator P/S|Rasio rega marang dodolan PTGX|Immunovant Inc (IMVT) - Rasio rega marang pendapatan|KNSA - Koefisien rega marang pendapatan|GRFS (Grifols Biemat) - Multiplikator P/S|Multiplikator P/S Adaptive Biotechnologies Inc.|Rasio rega marang pendapatan Celldex Therapeutics (CLDX)|Kapitalisasi marang pendapatan biocryst.com BCRX|Vera Therapeutics - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV - Multiplikator P/S|ABCL: Rasio rega marang pendapatan|Tourmaline Bio, Inc. (TRML) - Rasio rega marang pendapatan|Rega marang dodolan precigen.com (PGEN)|PHAR (pharming.com) - Multiplikator P/S|NKTR (Nektar Therapeutics Inc.) - Kapitalisasi marang volume dodolan|Multiplikator P/S UPB|ZBIO - Rega marang dodolan|Multiplikator P/S IMNM (immunome.com)|Gossamer Bio, Inc. - Rasio rega marang pendapatan|KalVista Pharmaceuticals, Inc. - Multiplikator P/S|SEPN (Septerna) - Rasio kapitalisasi marang pendapatan|Pieris Corp (PVLA) - Rasio rega marang pendapatan|SVRA - Koefisien rega marang pendapatan|RIGL (rigel.com) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan ANAB (AnaptysBio, Inc.)|Multiplikator P/S ATXS|enGene Holdings Inc (ENGN) - Multiplikator rega marang pendapatan|Multiplikator P/S RAPT (RAPT Therapeutics Inc.)|JBIO (Aerovate) - Rasio rega marang dodolan|ACRS: Kapitalisasi marang pendapatan|KYTX - Multiplikator P/S|TLSA: Multiplikator P/S|Kapitalisasi marang pendapatan Cabaletta Bio, Inc|Rasio rega marang pendapatan Ventyx Biosciences, Inc|THTX: Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan AVTX (Avalo Therapeutics, Inc)|Kapitalisasi marang pendapatan Eledon Pharmaceuticals ELDN|Rasio rega marang pendapatan Agenus, Inc. AGEN|Multiplikator P/S Climb Bio Inc. CLYM|ZURA - Rasio rega marang pendapatan|Rasio rega marang dodolan ATYR|ADAG (Adagene Inc.) - Kapitalisasi marang pendapatan|ImageneBio Inc (IMA) - Multiplikator P/S|Rasio rega marang pendapatan Shattuck Therapeutics|Kapitalisasi marang pendapatan equilliumbio.com (EQ)|Multiplikator P/S CNTB|Koefisien rega marang pendapatan Immunic Therapeutics|Multiplikator P/S ATRA (Atara Biotherapeutics, Inc.)|IFRX - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan X4 Pharmaceuticals, Inc. (XFOR)|ACET (adicetbio.com) - Rasio kapitalisasi marang pendapatan|CELU: Multiplikator P/S|INMB - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Barinthus Biotherapeutics plc|KZR: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S SABS|AKTX (Akari Therapeutics Plc) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ENLV (Enlivex Therapeutics Ltd)|q32bio.com - Rasio rega marang pendapatan|GOVX: Kapitalisasi marang pendapatan|edesabiotech.com (EDSA) - Kapitalisasi marang pendapatan|IBIO: Multiplikator P/S|CARM - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan XTLB|Kapitalisasi marang pendapatan boltbio.com (BOLT)|Rasio rega marang pendapatan HCW Biologics Inc (HCWB)|Multiplikator P/S Aptevo Therapeutics, Inc. (APVO)|Rasio rega marang pendapatan aimimmuno.com AIM|Rasio kapitalisasi pasar marang pendapatan ADTX|GRI Bio Corporation - Multiplikator P/S|XORTX Corp (XRTX) - Kapitalisasi marang pendapatan|HIND (Vyome Holdings Inc.) - Kapitalisasi marang pendapatan|revbiosciences.com (REVB) - Multiplikator P/S|INDP (Indaptus Corp) - Multiplikator P/S|Kapitalisasi marang pendapatan Scinai Immunotherapeutics Ltd (SCNI)|Rasio rega marang pendapatan CalciMedica Inc (CALI)|AFMD (Affimed NV) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ALLK (Allakos Inc.)|Multiplikator P/S HOOKIPA HOOK|IGMS: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ITOS (iTeos)|OCEA: Multiplikator P/S|TCBP (TC BioPharm Ltd) - Rasio rega marang pendapatan|THRD (Third Harmonic Bio Inc) - Multiplikator P/S